ClinicalTrials.gg
RecruitingNCT04933435Updated Oct 22, 2026

Interventional Radiology Liver Directed Therapies and Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients

An interventional study of Quality of life questionnaires in Liver Cancer and Hepatocellular Carcinoma (HCC), sponsored by Duke University. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Primary conditionCarcinoma, HepatocellularRegistry: Liver NeoplasmsReclassifiedWhy we changed it
Registry
Liver Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Hepatocellular
Why
  1. The study's listed conditions name Carcinoma, Hepatocellular, a narrower term within Liver Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Duke University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Nov 2020, registered Jun 2021).
  • Started Nov 2020; still recruiting 6 years later.
Updated Oct 22, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
78
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 926 studies in Carcinoma, Hepatocellular with a site in United States — 160 open to participants now, 245 under way, 17 of them phase 3. Carcinoma, Hepatocellular · United States.

Planned enrollment
225th of 775
78 · median 36
Started
2020
with 34 others
No phase
124 of 926
26 open now
Primary completion
2028-02
later than 168 of 244 live
Registered
707th of 926
by date

Among the 926 studies in Carcinoma, Hepatocellular with a site in United States, this one is the 225th largest by planned enrollment of the 775 interventional ones that give a count, is one of 35 that started in 2020, is one of 124 with no phase, reaches primary completion later than 168 of the 244 other live ones, and was the 707th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

160 of the 926 studies in Carcinoma, Hepatocellular with a site in United States are open now. Recruiting first, the newest first:

155 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 926 studies in Carcinoma, Hepatocellular with a site in United States, or all of them as a file.
02

Study summary

This is a research study to evaluate change in Quality of Life, as defined by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC C-30), from baseline to 1 month post treatment in two patient cohorts receiving Interventional Radiology Liver Directed Therapies or Hypofractionated Image-Guided Radiation Therapy.

03

Conditions studied

  • Liver Cancer
  • Hepatocellular Carcinoma (HCC)

Browse trials for

Keywords

  • Percutaneous local ablation (PLA)
  • Hypofractionated Image-Guided Radiation Therapy (HIGRT)
04

In context

Carcinoma, Hepatocellular Reclassified

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

This study's planned enrollment of 78 is above the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.

Browse Carcinoma, Hepatocellular studies →

Lead sponsor

Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.

Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.

Compared within Carcinoma, Hepatocellular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Liver Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • HCC diagnosed either by histology/pathology or Liver Imaging Reporting and Data System (LIRADs 5 per the ACR's LIRADs criteria 10) by CT or MRI
  • Patient is 18 years or older
  • Performance status of 0-2
  • score A5, A6, B7 or B8 (see Appendix)
  • Lesion ≤ 5cm in size
  • ≤ 3 lesions in the liver to be treated on protocol
  • Lesion amenable to treatment with both Interventional Radiology Liver Directed Therapies and HIGRT.

Exclusion criteria

Exclusion Criteria:

  • score B9 or Class C
  • Fluctuating ascites
  • Inability to complete baseline Quality of Life survey forms
  • Concurrent administration of systemic therapy for hepatocellular carcinoma
  • Prior liver radiation therapy is an exclusion unless subject participation is approved by the PI
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

06

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Active comparator
    Interventional Radiology Liver Directed Therapies (ILDT)

    ILDT includes ablations such as microwave ablation and percutaneous local ablation and embolotherapies including bland embolization, chemoembolization and radioembolization.

    Other: Quality of life questionnaires

  • Active comparator
    Hypofractionated Image-Guided Radiation Therapy (HIGRT)

    HIGRT is a non-invasive, outpatient procedure typically delivered in 3-10 fractions of radiation.

    Other: Quality of life questionnaires

Interventions

  • OtherQuality of life questionnaires

    European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep)

07

What researchers measure

Primary outcomes

  1. change in quality of life in patient cohorts receiving either Interventional Radiology Liver Directed Therapies or Hypofractionated Image-Guided Radiation Therapy

    as defined by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC C-30) measured from not at all (better) to very much (worse)

    Time frame: baseline, 1 month, 3 months, 6 months

Secondary outcomes

  1. change in quality of life in patients receiving Interventional Radiology Liver Directed Therapies or HIGRT

    as measured by the FACT-Hep survey questionnaire from not at all (better) to very much (worse)

    Time frame: baseline, 1 month, 3 months, 6 months

  2. number of patients with grade ≥2 acute toxicity that received Interventional Liver Directed Therapy

    Time frame: 90 days

  3. number of patients with grade ≥2 acute toxicity that received Hypofractionated Image Guided Radiation Therapy

    Time frame: 90 days

  4. total healthcare system cost associated with Interventional Radiology Liver Directed Therapies

    Time frame: 90 days

  5. total healthcare system cost associated with Hypofractionated Liver Directed Therapy

    Time frame: 90 days

08

Study locations

2 of 2 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Feb 2028, 87 months after the start.

Of 361 non-industry interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 87 months is above that.

Counting every sponsor, half of 385 studies reached it within 47 months; a quarter within 23 and three quarters within 75.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Feb 2027 → Feb 2028 and completion Feb 2027 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2021
First posted
Jun 21, 2021
StartActual
Nov 12, 2020
Primary completionEst.
Feb 2028was Feb 2027
CompletionEst.
Feb 2028was Feb 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Feb 2027→Feb 2028
Oct 22, 2026
Study completion
Feb 2027→Feb 2028
Oct 22, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Durham Veterans Administration Health Care System (DVAHCS) · Durham, United StatesContact person changed (no phone or email listed)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Primary completion Feb 2027→Feb 2028
    Study completion Feb 2027→Feb 2028
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Durham Veterans Administration Health Care System (DVAHCS) · Durham, United StatesContact person changed (no phone or email listed)
    + 3 other changes: verification date, conditions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04933435
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Jun 21, 2021
Start date
Nov 12, 2020
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Heather Franklin
Contact
heather.mccullough@duke.edu
(919) 668-3726
Linda Kaltenbach, PhD
Contact
Linda.Kaltenbach@duke.edu
Manisha Palta, MD
principal investigator · Duke Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion